I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
I-Mab (NASDAQ: IMAB), a US-based global biotech company specializing in precision immuno-oncology treatments for cancer, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The conference is scheduled to take place from April 7-10, 2025.
The company's management team will be present at this virtual healthcare event, which serves as a significant platform for biotechnology companies to showcase their developments and connect with industry stakeholders.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, IMAB declined 3.94%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in 24th Annual Needham Virtual Healthcare Conference, being held April 7-10, 2025.
Details are as follows:
| 24th Annual Needham Virtual Healthcare Conference | |
| Conference Date: | April 7-10, 2025 |
| Format: | Company Presentation and one-on-one meetings |
| Presentation Time: | Monday, April 7, 2025, 8:45 to 9:25 AM ET |
| Webcast Link: | Register here |
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.
I-Mab Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1 617-430-7579
pkelleher@lifesciadvisors.com
IR@imabbio.com